JP2023539542A - Ｃｏｖｉｄ－１９疾患を処置する新規組成物および方法 - Google Patents

Ｃｏｖｉｄ－１９疾患を処置する新規組成物および方法 Download PDF

Info

Publication number
JP2023539542A
JP2023539542A JP2022567359A JP2022567359A JP2023539542A JP 2023539542 A JP2023539542 A JP 2023539542A JP 2022567359 A JP2022567359 A JP 2022567359A JP 2022567359 A JP2022567359 A JP 2022567359A JP 2023539542 A JP2023539542 A JP 2023539542A
Authority
JP
Japan
Prior art keywords
patients
covid
composition
plerixafor
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022567359A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539542A5 (https=
Inventor
ベルガー，パトリック
デュパン，イザベル
プレヴェル，ルノー
ジェームス，クロエ
ジロデ，ピエール－オリヴィエ
ビスマス，ケレン
ラテンバッハ，リヴァイタル
ブレトン，ジェローム
トロッテン，フランソア
センシオ，ヴァレンティン
Original Assignee
フォーリビング バイオテック
ユニバーシティ デ ボルドー
センター ホスピタリエ デ ボルドー
インスティテュート ナショナル デ ラ サンテ エ デ ラ ルシェルシェ メディカル （インサーム）
インスティテュート パスツール デ リール
サントル ナショナル デ ラ ルシェルシュ シアンティフィック
ユニバーシティ デ リール
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フォーリビング バイオテック, ユニバーシティ デ ボルドー, センター ホスピタリエ デ ボルドー, インスティテュート ナショナル デ ラ サンテ エ デ ラ ルシェルシェ メディカル （インサーム）, インスティテュート パスツール デ リール, サントル ナショナル デ ラ ルシェルシュ シアンティフィック, ユニバーシティ デ リール filed Critical フォーリビング バイオテック
Publication of JP2023539542A publication Critical patent/JP2023539542A/ja
Publication of JP2023539542A5 publication Critical patent/JP2023539542A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022567359A 2020-05-07 2021-05-05 Ｃｏｖｉｄ－１９疾患を処置する新規組成物および方法 Pending JP2023539542A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20173595.8A EP3906922A1 (en) 2020-05-07 2020-05-07 New compositions and methods of treating covid-19 disease
EP20173595.8 2020-05-07
PCT/EP2021/061919 WO2021224356A1 (en) 2020-05-07 2021-05-05 New compositions and methods of treating covid-19 disease

Publications (2)

Publication Number Publication Date
JP2023539542A true JP2023539542A (ja) 2023-09-15
JP2023539542A5 JP2023539542A5 (https=) 2024-05-09

Family

ID=70617050

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022567359A Pending JP2023539542A (ja) 2020-05-07 2021-05-05 Ｃｏｖｉｄ－１９疾患を処置する新規組成物および方法

Country Status (9)

Country Link
US (1) US20230157994A1 (https=)
EP (2) EP3906922A1 (https=)
JP (1) JP2023539542A (https=)
KR (1) KR20240073720A (https=)
CN (1) CN116133657A (https=)
AU (1) AU2021269090A1 (https=)
BR (1) BR112022022578A2 (https=)
CA (1) CA3177779A1 (https=)
WO (1) WO2021224356A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023517616A (ja) * 2020-03-11 2023-04-26 バイオラインアールエックス・リミテッド 急性呼吸窮迫症候群およびウイルス感染の治療用のｃｘｃｒ４阻害剤
JP2023524522A (ja) * 2020-05-01 2023-06-12 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー． 抗ｃｏｖｉｄ－１９剤としてのｅタンパク質チャネル遮断薬およびｏｒｆ３阻害剤
WO2022197625A1 (en) * 2021-03-15 2022-09-22 Drugarray, Inc. Combination therapy for treating covid-19
WO2022197627A1 (en) * 2021-03-15 2022-09-22 Drugarray, Inc. Combination therapy for treating covid-19
WO2022197626A1 (en) * 2021-03-15 2022-09-22 Drugarray, Inc. Combination therapy for treating covid-19
EP4085910A1 (en) * 2021-05-05 2022-11-09 4Living Biotech Use of a compound such as plerixafor for treating a viral pulmonary disease
CN114099531A (zh) * 2021-12-16 2022-03-01 中国人民解放军军事科学院军事医学研究院 一种药物在治疗新型冠状病毒肺炎中的应用
WO2024092069A1 (en) * 2022-10-26 2024-05-02 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors for treatment of neurological diseases
CN121039852A (zh) 2023-06-07 2025-11-28 株式会社Lg新能源 锂金属电池及包含该锂金属电池的电池模组和电池包

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892563B2 (en) * 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
TW200811138A (en) * 2006-06-12 2008-03-01 Pfizer Prod Inc Pharmaceuticals
US20120064107A1 (en) * 2010-05-18 2012-03-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other disease
CN110982945B (zh) * 2020-03-04 2020-06-09 珠海丽珠试剂股份有限公司 一种检测2019新型冠状病毒的核酸组合物、试剂盒以及方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARCH BONE JT SURG, vol. 8 (Supplement 1), JPN6025019986, 2020, pages 226 - 230, ISSN: 0005597194 *
LIU ET AL., CELL DISCOVERY, vol. 6:16, JPN6025019987, 2020, ISSN: 0005597193 *

Also Published As

Publication number Publication date
EP4146195A1 (en) 2023-03-15
CA3177779A1 (en) 2021-11-11
CN116133657A (zh) 2023-05-16
AU2021269090A1 (en) 2022-12-01
KR20240073720A (ko) 2024-05-27
EP3906922A1 (en) 2021-11-10
WO2021224356A1 (en) 2021-11-11
US20230157994A1 (en) 2023-05-25
BR112022022578A2 (pt) 2023-01-17

Similar Documents

Publication Publication Date Title
JP2023539542A (ja) Ｃｏｖｉｄ－１９疾患を処置する新規組成物および方法
Baraldi et al. Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants
US11052073B1 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
US20210309733A1 (en) Methods for treating coronavirus infection and resulting inflammation-induced lung injury
Kumar et al. The chronicle of COVID-19 and possible strategies to curb the pandemic
US20230021647A1 (en) Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l
de Medeiros et al. Potential impact of the COVID-19 in HIV-infected individuals: a systematic review Impact of the COVID-19 in HIV-Infected Individuals
Ali et al. The role of tocilizumab in cytokine storm and improving outcomes in COVID-19
US20220363746A1 (en) Methods for treating coronavirus infection and resulting inflammation-induced lung injury
JP5172679B2 (ja) 呼吸器疾患の治療のためのインターフェロン−λ療法
KR20220139922A (ko) 인터페론 람다로의 코로나바이러스 감염의 치료
CN115443126A (zh) 用于预防或治疗SARS-CoV-2感染的相容性溶质
US20240317846A1 (en) Methods for treating coronavirus infection and resulting inflammation-induced lung injury
US20230192872A1 (en) Tocilizumab for the treatment of viral infections
KR20230041097A (ko) SARS-CoV-2 감염 환자의 결과를 개선하기 위한 흡입형 인터페론-베타
US20260041656A1 (en) Treating pulmonary hypertension based on novel biomarker
Adıyeke et al. Efficacy of Tocilizumab in the treatment of severe COVID-19 patients with respiratory failure: Treatment of Covid-19 pneumonia with Tocilizumab
RU2837859C1 (ru) Лечение коронавирусной инфекции
US20230109208A1 (en) Methods for treating coronavirus infection and resulting inflammation-induced lung injury
Sodani Potential pharmacological Therapeutics options for COVID-19
WO2023022616A1 (ru) Способ профилактики или лечения коронавирусной инфекции

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240423

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250520

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251118